MA72090B1 - Composés oxoisoindolinyl pipéridine-2,6-dione substitués - Google Patents

Composés oxoisoindolinyl pipéridine-2,6-dione substitués

Info

Publication number
MA72090B1
MA72090B1 MA72090A MA72090A MA72090B1 MA 72090 B1 MA72090 B1 MA 72090B1 MA 72090 A MA72090 A MA 72090A MA 72090 A MA72090 A MA 72090A MA 72090 B1 MA72090 B1 MA 72090B1
Authority
MA
Morocco
Prior art keywords
oxoisoindolinyl
dione
substitutes
piperidine
compounds
Prior art date
Application number
MA72090A
Other languages
English (en)
Inventor
John S. Tokarski
Andrew P. Degnan
Michael G. Yang
Zhonghui Lu
Vipin Yadav
James Kempson
Daniel Ferrante
Peter Kinam Park
Jinyi Zhu
Richard Charles BURRELL
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of MA72090B1 publication Critical patent/MA72090B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Sont divulgués des composés de formule (I) : (I) ou des stéréoisomères, tautomères ou sels de ceux-ci : R étant ; et le cycle A, L, R1, R2, R3, m et n étant tels que définis dans la description. Sont divulgués également des procédés d'utilisation de tels composés pour diminuer le niveau de la cycline E1 ; et des compositions pharmaceutiques comprenant de tels composés. Ces composés sont utiles dans le traitement de troubles prolifératifs, tels que le cancer.
MA72090A 2023-09-13 2024-09-12 Composés oxoisoindolinyl pipéridine-2,6-dione substitués MA72090B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202363582266P 2023-09-13 2023-09-13
PCT/US2024/046299 WO2025059245A1 (fr) 2023-09-13 2024-09-12 Composés oxoisoindolinyl pipéridine-2,6-dione substitués
EP24782711.6A EP4587429B1 (fr) 2023-09-13 2024-09-12 Composés oxoisoindolinyl pipéridine-2,6-dione substitués

Publications (1)

Publication Number Publication Date
MA72090B1 true MA72090B1 (fr) 2026-03-31

Family

ID=92931770

Family Applications (1)

Application Number Title Priority Date Filing Date
MA72090A MA72090B1 (fr) 2023-09-13 2024-09-12 Composés oxoisoindolinyl pipéridine-2,6-dione substitués

Country Status (13)

Country Link
US (1) US20250084056A1 (fr)
EP (1) EP4587429B1 (fr)
JP (1) JP7808733B2 (fr)
KR (1) KR20250068738A (fr)
AR (1) AR133800A1 (fr)
CO (1) CO2026002534A2 (fr)
DK (1) DK4587429T3 (fr)
FI (1) FI4587429T3 (fr)
LT (1) LT4587429T (fr)
MA (1) MA72090B1 (fr)
PT (1) PT4587429T (fr)
TW (1) TW202525792A (fr)
WO (1) WO2025059245A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120441535B (zh) * 2025-07-08 2025-09-30 苏州国匡医药科技有限公司 一种含炔基的gspt1降解剂及其应用

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
AU2006230099B2 (en) 2005-03-25 2012-04-19 Gitr, Inc. GITR binding molecules and uses therefor
CA2634198C (fr) 2005-12-20 2014-06-03 Incyte Corporation N-hydroxyamidinoheterocycles en tant que modulateurs d'indoleamine 2,3-dioxygenase
ES2444574T3 (es) 2006-09-19 2014-02-25 Incyte Corporation N-hidroxiamidinoheterociclos como moduladores de la indolamina 2,3-dioxigenasa
CL2007002650A1 (es) 2006-09-19 2008-02-08 Incyte Corp Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras.
EP1987839A1 (fr) 2007-04-30 2008-11-05 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Anticorps monoclonal cytotoxique anti-LAG-3 et son utilisation pour le traitement ou la prévention d'un rejet de greffe d'organe et de maladies auto-immunes
ES2776406T3 (es) 2007-07-12 2020-07-30 Gitr Inc Terapias de combinación que emplean moléculas de enlazamiento a GITR
EP2044949A1 (fr) 2007-10-05 2009-04-08 Immutep Utilisation de lag-3 recombinant ou ses dérivatifs pour déclencher la réponse immune des monocytes
JP5583592B2 (ja) 2007-11-30 2014-09-03 ニューリンク ジェネティクス コーポレイション Ｉｄｏ阻害剤
US20110176972A1 (en) 2008-05-29 2011-07-21 Saint-Gobain Centre De Recherches et D'Etudes Eur Cellular structure containing aluminium titanate
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
AU2009333580B2 (en) 2008-12-09 2016-07-07 Genentech, Inc. Anti-PD-L1 antibodies and their use to enhance T-cell function
EP2473531A4 (fr) 2009-09-03 2013-05-01 Merck Sharp & Dohme Anticorps anti-gitr
US8722720B2 (en) 2009-10-28 2014-05-13 Newlink Genetics Corporation Imidazole derivatives as IDO inhibitors
PH12012500881A1 (en) 2009-12-10 2017-07-26 Hoffmann La Roche Antibodies binding preferentially human csf1r extracellular domain 4 and their use
JP5998060B2 (ja) 2010-03-04 2016-09-28 マクロジェニクス，インコーポレーテッド Ｂ７−ｈ３と反応性のある抗体、その免疫学的に活性なフラグメントおよびその使用
CN102918061B (zh) 2010-03-05 2016-06-08 霍夫曼-拉罗奇有限公司 针对人csf-1r的抗体及其用途
CA2789076C (fr) 2010-03-05 2017-11-21 F. Hoffmann-La Roche Ag Anticorps contre les colonies humaines stimulant le recepteur du facteur-1 et ses utilisations
MX378336B (es) 2010-05-04 2025-03-10 Five Prime Therapeutics Inc Anticuerpos que se unen a factor estimulante de colonias 1 (csf1r).
PT2614082T (pt) 2010-09-09 2018-12-03 Pfizer Moléculas de ligação a 4-1bb
NO2694640T3 (fr) 2011-04-15 2018-03-17
KR101970025B1 (ko) 2011-04-20 2019-04-17 메디뮨 엘엘씨 Ｂ7-ｈ1 및 ｐｄ-1과 결합하는 항체 및 다른 분자들
HRP20201595T1 (hr) 2011-11-28 2020-12-11 Merck Patent Gmbh Anti-pd-l1 protutijela i njihova uporaba
BR112014012624A2 (pt) 2011-12-15 2018-10-09 F Hoffmann-La Roche Ag anticorpos, composição farmacêutica, ácido nucleico, vetores de expressão, célula hospedeira, método para a produção de um anticorpo recombinante e uso do anticorpo
RU2014136332A (ru) 2012-02-06 2016-03-27 Дженентек, Инк. Композиции и способы применения ингибиторов csf1r
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
EP2847220A1 (fr) 2012-05-11 2015-03-18 Five Prime Therapeutics, Inc. Méthodes destinées à traiter des affections avec des anticorps qui se lient au récepteur du facteur 1 de stimulation des colonies (csf1r)
AR091649A1 (es) 2012-07-02 2015-02-18 Bristol Myers Squibb Co Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
CN107759690A (zh) 2012-08-31 2018-03-06 戊瑞治疗有限公司 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法
EP3672939A1 (fr) 2017-08-21 2020-07-01 Celgene Corporation Procédés de préparation de (s)-tert-butyl 4,5-diamino-5-oxopentanoate
EP4278014A1 (fr) * 2021-01-13 2023-11-22 Monte Rosa Therapeutics, Inc. Traitement de cancers entraînés par myc avec des agents de dégradation gspt1
US20240408093A1 (en) * 2021-10-04 2024-12-12 Halda Therapeutics Opco, Inc. Heterobifunctional compounds and their use in treating disease
WO2023069720A1 (fr) * 2021-10-22 2023-04-27 Monte Rosa Therapeutics, Inc. Composés qui assurent la médiation de la dégradation de protéines et leurs procédés d'utilisation

Also Published As

Publication number Publication date
FI4587429T3 (fi) 2026-03-24
AR133800A1 (es) 2025-11-05
PT4587429T (pt) 2026-03-20
JP7808733B2 (ja) 2026-01-29
KR20250068738A (ko) 2025-05-16
US20250084056A1 (en) 2025-03-13
WO2025059245A1 (fr) 2025-03-20
DK4587429T3 (da) 2026-03-30
CO2026002534A2 (es) 2026-03-16
EP4587429B1 (fr) 2026-02-18
TW202525792A (zh) 2025-07-01
JP2026500094A (ja) 2026-01-06
EP4587429A1 (fr) 2025-07-23
LT4587429T (lt) 2026-03-25

Similar Documents

Publication Publication Date Title
MA52360B1 (fr) Dérivés de 2-amino-pyridine ou de 2-amino-pyrimidine utilisés en tant qu'inhibiteurs de kinases dépendantes des cyclines
MA54327B1 (fr) Inhibiteurs de kras g12c
MA67365B1 (fr) Dérivés de benzisoxazole sulfonamide
MA27774A1 (fr) Inhibiteurs de phosphatidylinositol 3-kinase
MA37891A1 (fr) Alcoxypyrazoles comme activateurs de guanylate cyclase soluble
MA55890B1 (fr) Modulateurs de thr-beta avec un groupe de tête dioxo-1,2,4-triazyl
MA31754B1 (fr) Cis-imidazolines chirales
WO2019035863A8 (fr) Activateurs de la pyruvate kinase destinés à être utilisés dans le traitement de troubles hématologiques
MA54608B1 (fr) Inhibiteurs aza-hétérobicycliques de mat2a et procédés d'utilisation pour le traitement du cancer
MA58181B1 (fr) Composés tricycliques substitués
MA47079A (fr) Composés amino-triazolopyidines et leur utilisation pour traiter le cancer
MA27568A1 (fr) Derives de pyrrolopyrimidine
MA28747B1 (fr) Dérivés de pyridine
TNSN04246A1 (fr) Derives d'heteroarylamides benzocondenses de thienopyridines utiles comme agents therapeutiques, compositions pharmaceutiques les contenant et methodes pour leur utilisation
TN2014000115A1 (fr) Derives de pyrrolopyrimidines et de purines
MA45920A (fr) Inhibiteurs de pyridopyrimidinone cdk2/4/6
MA56883B1 (fr) Dérivés de 2-hydroxycycloalcane-1-carbamoyle
MA30532B1 (fr) Sulfonamides tricycliques condenses inhibiteurs de gamma-secretase
MA28007A1 (fr) Composes organiques
TN2009000450A1 (fr) Derives de pyridine
MA28094A1 (fr) Dérivés [3.1.0] bicycliques servant d'inhibiteurs du transporteur de glycine
MA45222B1 (fr) Nouveaux dérivés de pipéridinyle, procédé de préparation de ceux-ci et compositions pharmaceutiques les contenant
MA27764A1 (fr) Acides carboxyliques alpha-substitués servant de modulateurs de PPAR
MA46229A (fr) Composés d'hétéroaryle carboxamide en tant qu'inhibiteurs de ripk2
MA26733A1 (fr) Derives d'isothiazole nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant